{
    "clinical_study": {
        "@rank": "78923", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the levels of hydroxyprogesterone caproate and it's metabolites in\n      blood throughout pregnancy\n\n      There will be 3 cohorts of subjects\n\n      Cohort 1 (6 subjects) will have daily blood draws in the morning at approximately the same\n      time each day for one week following their first dose of Makena and will have blood drawn\n      immediately prior to 2 successive Makena doses during Epoch 1 (24 - 28 weeks) and Epoch 2\n      (32 - 36 weeks)\n\n      Cohort 2 (8 subjects) will have blood drawn to determine the trough concentration 7 days\n      after their first dose of Makena.   Subjects will have daily blood draws for one week\n      following a dose of Makena given in Epoch 1 (24 - 28 weeks) and blood drawn immediately\n      prior to 2 successive doses during Epoch 2 (32 - 36 weeks)\n\n      Cohort 3 (16 subjects) will have blood drawn to determine the trough concentration 7 days\n      after their first dose of Makena.   Subjects will have blood drawn immediately prior to 2\n      successive  doses in Epoch 1 (24 - 28 weeks) and daily blood draws for one week following a\n      dose of Makena given during Epoch 2 (32 - 36 weeks)\n\n      A maximum of 10 subjects will be monitored on selected days following a completed course of\n      Makena therapy to determine the terminal elimination phase."
        }, 
        "brief_title": "Pharmacokinetic Study of Makena\u00ae (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pregnancy", 
        "condition_browse": {
            "mesh_term": "Premature Birth"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years.\n\n          -  Singleton gestation.\n\n          -  Gestational age 16 weeks 0 days to 20 weeks 6 days.\n\n          -  Previous singleton spontaneous preterm delivery\n\n        Exclusion Criteria:\n\n          -  Multifetal gestation.\n\n          -  Known major fetal anomaly or fetal demise.\n\n          -  Progestin treatment in any form in the 4 weeks prior to study entry.\n\n          -  Heparin therapy during current pregnancy or history of thromboembolic disease.\n\n          -  Maternal medical/obstetrical complications including hypertension requiring\n             medication or seizure disorder.\n\n          -  uterine anomaly other than fibroids\n\n          -  Known hypersensitivity to hydroxyprogesterone caproate injection or its components.\n\n          -  Any significant medical disorder that, in the opinion of the investigator, would be a\n             contraindication to the use of the drug or would preclude accurate evaluation of the\n             subject's condition or outcome or compromise the subject's safety in the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899846", 
            "org_study_id": "HPC-PK-005"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3"
            ], 
            "intervention_name": "Hydroxyprogesterone caproate 250 mg/ml", 
            "intervention_type": "Drug", 
            "other_name": [
                "Makena", 
                "17P"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "17-alpha-hydroxy-progesterone caproate", 
                "11-hydroxyprogesterone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Makena", 
            "Pharmacokinetics", 
            "Prior preterm delivery", 
            "Hydroxyprogesterone Caproate", 
            "17P"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lake Worth", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33461"
                    }, 
                    "name": "Altus Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Idaho Falls", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83404"
                    }, 
                    "name": "Rosemark WomenCare Specialists"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University Department of Obstetrics and Gynecology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "University of North Carolina at Chapel Hill Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53715"
                    }, 
                    "name": "The University of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-Center, Non-Randomized Pharmacokinetic Study of Makena\u00ae (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood of Women With a Singleton Pregnancy and a Previous Singleton Spontaneous Preterm Delivery", 
        "overall_official": {
            "affiliation": "KV Pharmaceutical Co.", 
            "last_name": "Robert Birch, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentrations of hydroxyprogesterone caproate and metabolites", 
            "safety_issue": "No", 
            "time_frame": "First dose, 24 - 28 weeks gestation, 32 - 36 weeks gestation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899846"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Plasma concentrations of hydroxyprogesterone caproate and metabolites", 
            "safety_issue": "No", 
            "time_frame": "Up to 28 days following last dose given in week 36"
        }, 
        "source": "Lumara Health, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lumara Health, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}